Heart Month
This February, AdvaMed® is working with member companies and our global partners to raise awareness and highlight the ways medical technology helps those living with cardiovascular disease live healthier, happier…
Diagnostics
Learn more about our Diagnostics work.
In Comments to FDA, AdvaMed® Maintains Support of Agency’s Authority to Regulate LDTs
Today, AdvaMedDx® submitted comments in response to the Food and Drug Administration’s Proposed Rule: Medical Devices; Laboratory Developed Tests. AdvaMedDx® is a division of AdvaMed® representing companies that develop in…
AdvaMed® Calls for Reauthorization of AIDS Relief Program
Today, AdvaMedDx®, a division of AdvaMed® representing manufacturers of innovative in vitro diagnostic tests, sent a letter urging Congressional leaders to prioritize the reauthorization of the President’s Emergency Plan for…
AdvaMed® Statement on Proposed Laboratory Developed Test Rule
AdvaMed®, the Medtech Association, released the following statement from President and CEO Scott Whitaker and Zach Rothstein, Executive Director of AdvaMedDx®, on FDA’s recently proposed LDT rule.
Dx Summit
The Dx Summit convenes leaders from the IVD and clinical diagnostic lab community to explore the most significant policies, technologies, and market shifts in the industry.
New AdvaMed®, Deloitte Research Defines Medtech’s Value in Health Care Ecosystem
Today, AdvaMed®, the MedTech Association, released updated reports, in collaboration with Deloitte on frameworks for the comprehensive assessment of medical technologies and diagnostic tests. These seminal reports had been developed…
AdvaMed®, GMTA Welcome World Health Assembly Resolution on the Importance of Diagnostic Products for Global Public Health
AdvaMed®, the Medtech Association, joined members the Global Medical Technology Alliance (GMTA) to welcome the recently released World Health Assembly (WHA) resolution on Strengthening Diagnostic Capacity.
Women’s Health Month: Closing Gaps in Breast Cancer Screening
This Women’s Health Month, AdvaMed® is highlighting new developments in breast cancer screening.
AdvaMed® Response to Senate HELP Committee Regarding Reauthorization of Pandemic All-Hazards Preparedness Act
On March 29, AdvaMed® responded to the Senate HELP Committee’s request for information on policy priorities for the reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA).
AdvaMed® Statement on Introduction of Bipartisan VALID Act
Today, AdvaMed®, the medtech association, released the following statement from President and CEO Scott Whitaker on the introduction of the bipartisan Verifying Accurate, Leading-edge IVCT Development (VALID) Act. Introduced in…